Headlines about a CVS insulin settlement are easy to misread as "there's a check coming." There isn't one for consumers — but there is a practical lesson here about how your insulin refills get billed.
What Is This About?
CVS has agreed to pay to resolve government allegations that it overbilled taxpayer-funded health programs for insulin pens. You will see the deal reported as both a $36.5 million settlement and a $37.76 million settlement — those are not two different cases. The $36.5 million figure is the one a multistate coalition of attorneys general uses; the $37.76 million figure is the federal Justice Department's framing, which also counts Medicare, TRICARE, and the Federal Employees Health Benefits Program. It is one settlement, resolving the same conduct.The U.S. Attorney's Office for the Southern District of New York and the Department of Health and Human Services Office of Inspector General announced the resolution on December 2, 2025, and state attorneys general — including New Jersey, New York, Connecticut, and California — have rolled out their own announcements into 2026 describing their states' shares. New Jersey's slice alone, for example, was $365,725. The case started as a whistleblower lawsuit brought by a former CVS pharmacist.
What CVS Was Accused Of
The government's case was about how CVS dispensed and billed for insulin pens, which come in cartons of multiple pens. According to the Justice Department, from 2010 to 2020 many CVS pharmacies dispensed full cartons without breaking them open, sometimes exceeding the days-of-supply limits set by insurance plans; instructed staff to report the maximum plan-allowed days of supply rather than the amount actually dispensed, which masked premature refills from the pharmacy benefit managers that process the claims; and let pharmacy software trigger early automatic refills. The result, the government said, was that Medicaid, Medicare, and other programs paid CVS for insulin refills that were not eligible for reimbursement.Unlike a typical "no admission" settlement, this one includes some acceptance of responsibility. Per the Justice Department, CVS admitted certain facts — that many of its pharmacies dispensed insulin pens without breaking open cartons and that government programs paid it for refills ineligible for reimbursement — while the broader allegations were resolved without a full admission of liability. The claims were brought under the federal False Claims Act.
Why There's No Money for Consumers
This is a government recovery, not a class action, so it is important to be clear: there is no consumer claim form, no settlement fund for patients, and nothing to file. The money is repayment to the government for improperly billed claims. It flows to the U.S. Treasury and to participating states' Medicaid programs.The one private party who shares in the recovery is the whistleblower. The case began as a qui tam (whistleblower) complaint filed under seal in 2018 by a former CVS pharmacist, and under the False Claims Act a whistleblower is entitled to a percentage of the government's recovery — here reported at 19.5%. That statutory share is the only slice earmarked for a private individual, and it is not something any patient can apply for. This is the same structure behind the much larger $440 million Omnicare / CVS nursing-home settlement — another CVS-related False Claims Act case that produced no consumer payout.
The Practical Takeaway for Insulin Patients
Even without a check to claim, there is a useful lesson here for anyone who fills insulin at a pharmacy. The billing practices the government described — early auto-refills and cartons dispensed beyond what a prescription called for — are the kind of thing that can leave patients with automatic refill prompts arriving too soon and stockpiles of unused insulin building up in the fridge. Insulin has an expiration date, and product that piles up faster than you use it can go to waste.If you take insulin, it is worth keeping a loose eye on your refill timing: whether refills seem to arrive before you actually need them, and whether you are accumulating more unopened pens than you will use before they expire. If something looks off, raise it with your pharmacy. That is a general awareness point, not medical or financial advice — your prescriber and pharmacist are the right people to sort out your specific regimen.
Don't Confuse It With the Other CVS Insulin Matter
There is a separate CVS insulin story making the rounds that is easy to mix up with this one: a proposed settlement in a Federal Trade Commission case focused on insulin pricing and the role of CVS's pharmacy benefit manager in how insulin list prices and rebates are set. That is a different agency, a different theory (pricing, not over-dispensing), and a different case. This page is only about the False Claims Act over-dispensing settlement.Frequently Asked Questions
Can consumers claim money from the CVS insulin settlement?
No. This is a False Claims Act recovery paid to the federal government and state Medicaid programs, plus a whistleblower share. There is no consumer claim form, no settlement fund for patients, and nothing for the public to file.
Is the settlement $36.5 million or $37.76 million?
It is one settlement described two ways. The $36.5 million figure is what the multistate attorneys general use; the $37.76 million figure is the federal Justice Department framing that also counts Medicare, TRICARE and the Federal Employees Health Benefits Program. They are not two separate settlements.
What did CVS allegedly do?
The government alleged that from 2010 to 2020 CVS overbilled government health programs for insulin pens — dispensing full pen cartons without breaking them open (exceeding days-of-supply limits), reporting the maximum plan-allowed days of supply rather than the amount actually dispensed, and letting software trigger early auto-refills, so the programs paid for refills that were not eligible for reimbursement. CVS admitted certain of this conduct while the broader allegations were resolved without a full admission of liability.
Did CVS admit wrongdoing?
Partly. According to the Justice Department, CVS accepted responsibility for certain facts — that many of its pharmacies dispensed insulin pens without breaking open cartons and that government programs paid it for refills ineligible for reimbursement — but it did not admit all of the allegations. It is not a blanket no-admission settlement.
What's the practical takeaway for insulin patients?
The billing practices the government described could cause diabetic patients to get automatic refill prompts too early and build up stockpiles of unused insulin that can expire. If you take insulin, it is worth keeping an eye on your refill timing and how much unused product you are accumulating, and raising it with your pharmacy if refills seem to arrive sooner than you need them.
Sources
- U.S. Attorney's Office, S.D.N.Y. — $37.76 Million Settlement With CVS Over Dispensing Insulin Pens
- HHS Office of Inspector General — Settlement Announcement
- New York Attorney General — Secures $36.5 Million From CVS Over Medicaid Billing
- California Attorney General — CVS to Pay $36.5 Million Over Overbilling Allegations
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
